Sports Medicine Joint Repair was Smith & Nephew’s largest revenue line in fiscal 2025, bringing in $1.07B of $6.16B (17%).
| Products and services [axis] | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Knee Implants | $899.00M | $940.00M | $977.00M | $1.01B | |||||||
| Sports Medicine Joint Repair | $870.00M | $945.00M | $982.00M | $1.07B | |||||||
| Advanced Wound Care | $712.00M | $725.00M | $735.00M | $766.00M | |||||||
| Arthroscopic Enabling Technologies | $567.00M | $588.00M | $632.00M | $647.00M | |||||||
| Hip Implants | $584.00M | $599.00M | $619.00M | $641.00M | |||||||
| Trauma & Extremities | $543.00M | $564.00M | $608.00M | $649.00M | |||||||
| Trauma | — | — | — | — | |||||||
| Advanced Wound Bioactives | $520.00M | $553.00M | $581.00M | $621.00M | |||||||
| Other Surgical Businesses | — | — | — | — | |||||||
| Advanced Wound Devices | $280.00M | $328.00M | $365.00M | $406.00M | |||||||
| Ent (Ear, Nose & Throat) | $153.00M | $196.00M | $210.00M | $220.00M | |||||||
| Other Reconstruction | $87.00M | $111.00M | $101.00M | $136.00M | |||||||
| Total | $5.22B | $5.55B | $5.81B | $6.16B |
Smith & Nephew brought in $6.16B from its 10 revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 6.1% from $5.81B in fiscal 2024. Sports Medicine Joint Repair was the largest at $1.07B (17.3%), ahead of Knee Implants at $1.01B (16.4%) and Advanced Wound Care at $766.00M (12.4%). The other seven revenue lines brought in $3.32B combined.
Compared with fiscal 2024, Other Reconstruction grew fastest, up 34.7% to $136.00M. Every revenue line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $5.22B to $6.16B, a compound annual growth rate of 5.7%. Sports Medicine Joint Repair's share of the total rose from 16.7% to 17.3%.
Orthopaedics was Smith & Nephew’s largest segment in fiscal 2025, bringing in $2.44B of $6.16B (40%).
| Segments [axis] | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Orthopaedics | $2.11B | $2.21B | $2.31B | $2.44B | |||||
| Sports Medicine & Ent | $1.59B | $1.73B | $1.82B | $1.93B | |||||
| Advanced Wound Management | $1.51B | $1.61B | $1.68B | $1.79B | |||||
| Total | $5.22B | $5.55B | $5.81B | $6.16B |
Smith & Nephew brought in $6.16B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 6.1% from $5.81B in fiscal 2024. Orthopaedics was the largest at $2.44B (39.5%), ahead of Sports Medicine & Ent at $1.93B (31.4%) and Advanced Wound Management at $1.79B (29.1%).
Compared with fiscal 2024, Advanced Wound Management grew fastest, up 6.7% to $1.79B. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments grew from $5.22B to $6.16B, a compound annual growth rate of 5.7%. Orthopaedics' share of the total fell from 40.5% to 39.5%.
Established Markets was Smith & Nephew’s largest region in fiscal 2025, bringing in $5.16B of $6.16B (84%).
| Markets of customers [axis] | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Established Markets | $4.27B | $4.59B | $4.83B | $5.16B | ||||||
| Emerging Markets | $947.00M | $959.00M | $980.00M | $1.00B | ||||||
| Total | $5.22B | $5.55B | $5.81B | $6.16B |
Smith & Nephew brought in $6.16B from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 6.1% from $5.81B in fiscal 2024. Established Markets was the largest at $5.16B (83.7%), ahead of Emerging Markets at $1.00B (16.3%).
Compared with fiscal 2024, Established Markets grew 6.9% to $5.16B and Emerging Markets grew 2.3% to $1.00B. From fiscal 2022 to 2025, combined revenue from these regions grew from $5.22B to $6.16B, a compound annual growth rate of 5.7%. Established Markets' share of the total rose from 81.8% to 83.7%.
Smith & Nephew (SNN) reports its revenue by products and services [axis], by segments [axis] and by markets of customers [axis]. In fiscal 2025, Sports Medicine Joint Repair was its largest revenue line, bringing in $1.07B (17.3% of the total), followed by Knee Implants at $1.01B (16.4%).
Sports Medicine Joint Repair was Smith & Nephew's largest revenue line in fiscal 2025, bringing in $1.07B, or 17.3% of the $6.16B total across its 10 revenue lines.
Orthopaedics was Smith & Nephew's largest segment in fiscal 2025, bringing in $2.44B, or 39.5% of the $6.16B total across its three segments.
Established Markets was Smith & Nephew's largest region in fiscal 2025, bringing in $5.16B, or 83.7% of the $6.16B total across its two regions.
Among Smith & Nephew's revenue lines that make up at least 2% of revenue, Other Reconstruction grew fastest in fiscal 2025, up 34.7% from $101.00M to $136.00M.
Every figure comes from Smith & Nephew's annual financial filings, as reported. Each line keeps the name Smith & Nephew gives it, and years follow its fiscal calendar.
Smith & Nephew's revenue by products and services [axis] goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.